ReP USP - Resultado da busca

Artigo de periodico
Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: differential neutralization of SARS-CoV-2 omicron variants (2025)
Daher, Isabela Pazotti ; Almeida, Bianca da Silva ; Souza-Silva, Guilherme Antonio de ; Marques, Rodolfo Ferreira ; Soares, Gustavo Henrique Corrêa ; Andreata-Santos, Robert ; Moretti, Ana ; Silva, Mariângela de Oliveira ; Schuch, Viviane ; Sasahara, Greyce Luri ; Kuramoto, Andréia; Yamamoto, Márcio ; Santos, Keity ; Coelho, Veronica Porto Carreiro de Vasconcellos ; Kalil Filho, Jorge Elias ; Rosa, Daniela Santoro ; Cunha Neto, Edecio ; Ferreira, Luís Carlos de Souza ; Boscardin, Silvia Beatriz
Source: Clinical Immunology. Unidades: ICB, FM, FCF
Subjects: MICROBIOLOGIA, PARASITOLOGIA, VARIAÇÃO GENÉTICA, COVID-19, VACINAS VIRAIS, NEUTRALIZAÇÃO, CORONAVIRUS, VÍRUS DE RNA, INFECÇÕES POR VÍRUS DE RNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DAHER, Isabela Pazotti et al. Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: differential neutralization of SARS-CoV-2 omicron variants. Clinical Immunology, v. 276, p. 12 , 2025Tradução . . Disponível em: https://doi.org/10.1016/j.clim.2025.110492. Acesso em: 26 jun. 2025.
APA
Daher, I. P., Almeida, B. da S., Souza-Silva, G. A. de, Marques, R. F., Soares, G. H. C., Andreata-Santos, R., et al. (2025). Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: differential neutralization of SARS-CoV-2 omicron variants. Clinical Immunology, 276, 12 . doi:10.1016/j.clim.2025.110492
NLM
Daher IP, Almeida B da S, Souza-Silva GA de, Marques RF, Soares GHC, Andreata-Santos R, Moretti A, Silva M de O, Schuch V, Sasahara GL, Kuramoto A, Yamamoto M, Santos K, Coelho VPC de V, Kalil Filho JE, Rosa DS, Cunha Neto E, Ferreira LC de S, Boscardin SB. Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: differential neutralization of SARS-CoV-2 omicron variants [Internet]. Clinical Immunology. 2025 ; 276 12 .[citado 2025 jun. 26 ] Available from: https://doi.org/10.1016/j.clim.2025.110492
Vancouver
Daher IP, Almeida B da S, Souza-Silva GA de, Marques RF, Soares GHC, Andreata-Santos R, Moretti A, Silva M de O, Schuch V, Sasahara GL, Kuramoto A, Yamamoto M, Santos K, Coelho VPC de V, Kalil Filho JE, Rosa DS, Cunha Neto E, Ferreira LC de S, Boscardin SB. Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: differential neutralization of SARS-CoV-2 omicron variants [Internet]. Clinical Immunology. 2025 ; 276 12 .[citado 2025 jun. 26 ] Available from: https://doi.org/10.1016/j.clim.2025.110492
Artigo de periodico
Enhanced immunogenicity and protective effects against SARS-CoV-2 following immunization with a recombinant RBD-IgG chimeric protein (2024)
Silva, Mariângela de Oliveira ; Castro-Amarante, Maria Fernanda ; Carvalho, Alexia Adrianne Venceslau Brito ; Almeida, Bianca da Silva; Daher, Isabela Pazotti ; Souza-Silva, Guilherme Antonio de ; Yamamoto, Marcio Massao ; Koike, Gabriela ; Souza, Edmarcia Elisa de ; Wrenger, Carsten ; Ferreira, Luis Carlos de Souza ; Boscardin, Silvia Beatriz
Source: Vaccines. Unidades: ICB, FM
Subjects: PARASITOLOGIA, MICROBIOLOGIA, PROTEÍNAS RECOMBINANTES, PROTEÍNAS SANGUÍNEAS, ANTICORPOS, IMUNOGENICIDADE DA VACINA, IMUNOGENÉTICA, IMUNOGLOBULINAS, COVID-19, VACINAS VIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Mariângela de Oliveira et al. Enhanced immunogenicity and protective effects against SARS-CoV-2 following immunization with a recombinant RBD-IgG chimeric protein. Vaccines, v. 12, n. 4, p. 14 , 2024Tradução . . Disponível em: https://doi.org/10.3390/vaccines12040356. Acesso em: 26 jun. 2025.
APA
Silva, M. de O., Castro-Amarante, M. F., Carvalho, A. A. V. B., Almeida, B. da S., Daher, I. P., Souza-Silva, G. A. de, et al. (2024). Enhanced immunogenicity and protective effects against SARS-CoV-2 following immunization with a recombinant RBD-IgG chimeric protein. Vaccines, 12( 4), 14 . doi:10.3390/vaccines12040356
NLM
Silva M de O, Castro-Amarante MF, Carvalho AAVB, Almeida B da S, Daher IP, Souza-Silva GA de, Yamamoto MM, Koike G, Souza EE de, Wrenger C, Ferreira LC de S, Boscardin SB. Enhanced immunogenicity and protective effects against SARS-CoV-2 following immunization with a recombinant RBD-IgG chimeric protein [Internet]. Vaccines. 2024 ; 12( 4): 14 .[citado 2025 jun. 26 ] Available from: https://doi.org/10.3390/vaccines12040356
Vancouver
Silva M de O, Castro-Amarante MF, Carvalho AAVB, Almeida B da S, Daher IP, Souza-Silva GA de, Yamamoto MM, Koike G, Souza EE de, Wrenger C, Ferreira LC de S, Boscardin SB. Enhanced immunogenicity and protective effects against SARS-CoV-2 following immunization with a recombinant RBD-IgG chimeric protein [Internet]. Vaccines. 2024 ; 12( 4): 14 .[citado 2025 jun. 26 ] Available from: https://doi.org/10.3390/vaccines12040356
Artigo de periodico
Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals (2024)
Adami, Flávia Lopes ; Castro, Mateus Vidigal de ; Almeida, Bianca da Silva ; Daher, Isabela Pazotti ; Yamamoto, Marcio Massao ; Santos, Keity Souza ; Zatz, Mayana ; Naslavsky, Michel Satya ; Rosa, Daniela Santoro ; Cunha Neto, Edecio ; Oliveira, Vivian Leite de ; Kalil Filho, Jorge Elias ; Boscardin, Silvia Beatriz
Source: Frontiers in Immunology. Unidades: ICB, FM, IB
Subjects: PARASITOLOGIA, ANTIVIRAIS, COVID-19, CORONAVIRUS, INFECÇÕES POR CORONAVIRUS, IMUNOGLOBULINAS, GLICOPROTEÍNAS, ESTUDOS DE COORTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ADAMI, Flávia Lopes et al. Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals. Frontiers in Immunology, v. 15, p. 10 , 2024Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2024.1396603. Acesso em: 26 jun. 2025.
APA
Adami, F. L., Castro, M. V. de, Almeida, B. da S., Daher, I. P., Yamamoto, M. M., Santos, K. S., et al. (2024). Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals. Frontiers in Immunology, 15, 10 . doi:10.3389/fimmu.2024.1396603
NLM
Adami FL, Castro MV de, Almeida B da S, Daher IP, Yamamoto MM, Santos KS, Zatz M, Naslavsky MS, Rosa DS, Cunha Neto E, Oliveira VL de, Kalil Filho JE, Boscardin SB. Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals [Internet]. Frontiers in Immunology. 2024 ; 15 10 .[citado 2025 jun. 26 ] Available from: https://doi.org/10.3389/fimmu.2024.1396603
Vancouver
Adami FL, Castro MV de, Almeida B da S, Daher IP, Yamamoto MM, Santos KS, Zatz M, Naslavsky MS, Rosa DS, Cunha Neto E, Oliveira VL de, Kalil Filho JE, Boscardin SB. Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals [Internet]. Frontiers in Immunology. 2024 ; 15 10 .[citado 2025 jun. 26 ] Available from: https://doi.org/10.3389/fimmu.2024.1396603
Artigo de periodico
Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape (2023)
Oliveira, Jamille Ramos ; Ruiz, Cesar Manuel Remuzgo ; Machado, Rafael Rahal Guaragna ; Urbanski, Alysson Henrique ; Magawa, Jhosiene Yukari; Daher, Isabela Pazotti; Urbanski, Alysson Henrique ; Schmitz, Gabriela Justamante Händel ; Arcuri, Helen Andrade; Ferreira, Marcelo Alves ; Sasahara, Greyce Luri ; Medeiros, Giuliana Xavier de ; Silva Júnior, Roberto Carlos Vieira da ; Rosa, Daniela Santoro ; Nakaya, Helder Takashi Imoto ; Gadermaier, Gabriele; Coelho, Verônica ; Santos, Keity Souza ; Durigon, Edison Luiz ; Boscardin, Silvia Beatriz ; Schechtman, Deborah ; Cunha Neto, Edecio; Kalil Filho, Jorge Elias ; Coelho, Veronica Porto Carreiro de Vasconcellos
Source: Frontiers in Immunology. Unidades: ICB, IQ, FM, FCF
Subjects: MICROBIOLOGIA, PARASITOLOGIA, ANTICORPOS, COVID-19, VACINAS VIRAIS, EPITOPOS, IMUNOGLOBULINAS, VARIAÇÃO GENÉTICA, MUTAÇÃO GENÉTICA, PEPTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Jamille Ramos et al. Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. Frontiers in Immunology, v. 13, p. 1-15, 2023Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.1010105. Acesso em: 26 jun. 2025.
APA
Oliveira, J. R., Ruiz, C. M. R., Machado, R. R. G., Urbanski, A. H., Magawa, J. Y., Daher, I. P., et al. (2023). Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. Frontiers in Immunology, 13, 1-15. doi:10.3389/fimmu.2022.1010105
NLM
Oliveira JR, Ruiz CMR, Machado RRG, Urbanski AH, Magawa JY, Daher IP, Urbanski AH, Schmitz GJH, Arcuri HA, Ferreira MA, Sasahara GL, Medeiros GX de, Silva Júnior RCV da, Rosa DS, Nakaya HTI, Gadermaier G, Coelho V, Santos KS, Durigon EL, Boscardin SB, Schechtman D, Cunha Neto E, Kalil Filho JE, Coelho VPC de V. Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape [Internet]. Frontiers in Immunology. 2023 ; 13 1-15.[citado 2025 jun. 26 ] Available from: https://doi.org/10.3389/fimmu.2022.1010105
Vancouver
Oliveira JR, Ruiz CMR, Machado RRG, Urbanski AH, Magawa JY, Daher IP, Urbanski AH, Schmitz GJH, Arcuri HA, Ferreira MA, Sasahara GL, Medeiros GX de, Silva Júnior RCV da, Rosa DS, Nakaya HTI, Gadermaier G, Coelho V, Santos KS, Durigon EL, Boscardin SB, Schechtman D, Cunha Neto E, Kalil Filho JE, Coelho VPC de V. Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape [Internet]. Frontiers in Immunology. 2023 ; 13 1-15.[citado 2025 jun. 26 ] Available from: https://doi.org/10.3389/fimmu.2022.1010105
Artigo de periodico
Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape (2021)
Santos, Keity Souza ; Oliveira, Jamille Ramos de ; Machado, Rafael Rahal Guaragna ; Arcuri, Helen Andrade; Magawa, Jhosiene Yukari; Daher, Isabela Pazotti; Urbanski, Alysson Henrique; Schmitz, Gabriela Justamante Handel; Silva Júnior, Roberto Carlos Vieira; Durigon, Edison Luiz ; Boscardin, Silvia Beatriz ; Rosa, Daniela Santoro ; Schechtman, Deborah ; Cunha Neto, Edecio ; Gadermaier, Gabriele; Coelho, Verônica Porto Carreiro de Vasconcellos; Kalil, Jorge; Nakaya, Helder Takashi Imoto
Source: medRxiv (The Preprint Server For Health Sciences). Unidades: FM, ICB, IQ, FCF
Subjects: EPITOPOS, COVID-19, ANTICORPOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Keity Souza et al. Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape. medRxiv (The Preprint Server For Health Sciences), p. 18 , 2021Tradução . . Disponível em: https://doi.org/10.1101/2021.03.11.21253399. Acesso em: 26 jun. 2025.
APA
Santos, K. S., Oliveira, J. R. de, Machado, R. R. G., Arcuri, H. A., Magawa, J. Y., Daher, I. P., et al. (2021). Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape. medRxiv (The Preprint Server For Health Sciences), 18 . doi:10.1101/2021.03.11.21253399
NLM
Santos KS, Oliveira JR de, Machado RRG, Arcuri HA, Magawa JY, Daher IP, Urbanski AH, Schmitz GJH, Silva Júnior RCV, Durigon EL, Boscardin SB, Rosa DS, Schechtman D, Cunha Neto E, Gadermaier G, Coelho VPC de V, Kalil J, Nakaya HTI. Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape [Internet]. medRxiv (The Preprint Server For Health Sciences). 2021 ; 18 .[citado 2025 jun. 26 ] Available from: https://doi.org/10.1101/2021.03.11.21253399
Vancouver
Santos KS, Oliveira JR de, Machado RRG, Arcuri HA, Magawa JY, Daher IP, Urbanski AH, Schmitz GJH, Silva Júnior RCV, Durigon EL, Boscardin SB, Rosa DS, Schechtman D, Cunha Neto E, Gadermaier G, Coelho VPC de V, Kalil J, Nakaya HTI. Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape [Internet]. medRxiv (The Preprint Server For Health Sciences). 2021 ; 18 .[citado 2025 jun. 26 ] Available from: https://doi.org/10.1101/2021.03.11.21253399

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Subjects

Non normalized affiliation